Preoperative Radiotherapy in Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 10920
Special Issue Editor
Interests: breast cancer; stereotactic radiotherapy; intraoperative radiotherapy; radiotherapy for pediatric patients; radiotherapy for elderly patients
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Today, preoperative radiotherapy is the standard of care in several tumor entities, as its superiority has been shown in randomized trials in the past.
In advanced rectal cancer, neoadjuvant radiochemotherapy achieves significantly better local control and functional outcomes than postoperative radiochemotherapy.
In soft tissue sarcomas, preoperative radiotherapy of 50 Gy in 25 fractions was equivalent in terms of local tumor control to a 32% higher dose (66 Gy in 33 fractions) of postoperative radiotherapy. There was less late radiation-induced tissue fibrosis after preoperative radiotherapy and the overall survival was significantly improved.
In Stage III NSCLC, preoperative radiochemotherapy (45 Gy, 1.5 Gy BID in 3 weeks) is equivalent to postoperative radiochemotherapy (54 Gy, 1.8 Gy in 6 weeks). Nonetheless, DFS and overall survival were superior in the preoperative arm in patients who underwent surgical resection.
In breast cancer, preoperative radiotherapy has yet to be established.
Applying adjuvant radiotherapy reduces ipsilateral breast recurrences, breast-cancer-specific mortality, and overall mortality significantly. The same advantages can be expected when applying preoperative irradiation. Administering radiotherapy preoperatively would definitely improve the cosmetic outcome in patients undergoing partial mastectomy or mastectomy with immediate reconstruction with autologous flabs. Shrinkage and fibrosis of the flab can be expected to be significantly lower compared with flabs receiving postoperative radiotherapy, as they are not irradiated.
In all cancers, the target volume can be defined more accurately in the preoperative setting than in the postoperative setting after tumor removal.
This Special issue will focus on preoperative radiotherapy in different cancers concerning oncologic endpoints, acute and late side effects, and quality of life.
Dr. Christiane Matuschek
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- radiotherapy
- preoperative radiotherapy
- meta-analysis